1
|
Roels S, Costa OR, Tersey SA, Stangé G, De Smet D, Balti EV, Gillard P, Keymeulen B, Ling Z, Pipeleers DG, Gorus FK, Mirmira RG, Martens GA. Combined Analysis of GAD65, miR-375, and Unmethylated Insulin DNA Following Islet Transplantation in Patients With T1D. J Clin Endocrinol Metab 2019; 104:451-460. [PMID: 30203041 PMCID: PMC6310912 DOI: 10.1210/jc.2017-02520] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2017] [Accepted: 07/30/2018] [Indexed: 02/07/2023]
Abstract
AIM Several biomarkers have been proposed to detect pancreatic β cell destruction in vivo but so far have not been compared for sensitivity and significance. METHODS We used islet transplantation as a model to compare plasma concentrations of miR-375, 65-kDa subunit of glutamate decarboxylase (GAD65), and unmethylated insulin DNA, measured at subpicomolar sensitivity, and study their discharge kinetics, power for outcome prediction, and detection of graft loss during follow-up. RESULTS At 60 minutes after transplantation, GAD65 and miR-375 consistently showed near-equimolar and correlated increases proportional to the number of implanted β cells. GAD65 and miR-375 showed comparable power to predict poor graft outcome at 2 months, with areas under the curve of 0.833 and 0.771, respectively (P = 0.53). Using receiver operating characteristic analysis, we defined likelihood ratios (LRs) for rationally selected result intervals. In GADA-negative recipients (n = 28), GAD65 <4.5 pmol/L (LR = 0.15) and >12.2 pmol/L (LR = ∞) predicted good and poor outcomes, respectively. miR-375 could be used in all recipients irrespective of GAD65 autoantibody status (n = 46), with levels <1.4 pmol/L (LR = 0.14) or >7.6 pmol/L (LR = 9.53) as dual thresholds. The posttransplant surge of unmethylated insulin DNA was inconsistent and unrelated to outcome. Combined measurement of these three biomarkers was also tested as liquid biopsy for β cell death during 2-month follow-up; incidental surges of GAD65, miR-375, and (un)methylated insulin DNA, alone or combined, were confidently detected but could not be related to outcome. CONCLUSIONS GAD65 and miR-375 performed equally well in quantifying early graft destruction and predicting graft outcome, outperforming unmethylated insulin DNA.
Collapse
Affiliation(s)
- Sarah Roels
- Diabetes Research Center, Brussels Free University, Brussels, Belgium
| | - Olivier R Costa
- Diabetes Research Center, Brussels Free University, Brussels, Belgium
- Department of Clinical Biology, University Hospital Brussels (UZ Brussel), Brussels, Belgium
| | - Sarah A Tersey
- Department of Pediatrics, IU Center for Diabetes and Metabolic Disease, Indiana University School of Medicine, Indianapolis, Indiana
| | - Geert Stangé
- Diabetes Research Center, Brussels Free University, Brussels, Belgium
| | - Dieter De Smet
- Department of Laboratory Medicine, AZ Delta, Roeselare, Belgium
| | - Eric V Balti
- Diabetes Research Center, Brussels Free University, Brussels, Belgium
| | - Pieter Gillard
- Department of Endocrinology, University Hospitals Leuven – Katholieke Universiteit Leuven, Leuven, Belgium
| | - Bart Keymeulen
- Diabetes Research Center, Brussels Free University, Brussels, Belgium
- Department of Clinical Biology, University Hospital Brussels (UZ Brussel), Brussels, Belgium
| | - Zhidong Ling
- Diabetes Research Center, Brussels Free University, Brussels, Belgium
- Department of Clinical Biology, University Hospital Brussels (UZ Brussel), Brussels, Belgium
| | | | - Frans K Gorus
- Diabetes Research Center, Brussels Free University, Brussels, Belgium
| | - Raghavendra G Mirmira
- Department of Pediatrics, IU Center for Diabetes and Metabolic Disease, Indiana University School of Medicine, Indianapolis, Indiana
- Departments of Biochemistry and Molecular Biology, Medicine, and Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana
| | - Geert A Martens
- Diabetes Research Center, Brussels Free University, Brussels, Belgium
- Department of Laboratory Medicine, AZ Delta, Roeselare, Belgium
- Correspondence and Reprint Requests: Geert A. Martens, MD, PhD, Diabetes Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium. E-mail:
| |
Collapse
|
2
|
Costa OR, Stangé G, Verhaeghen K, Brackeva B, Nonneman E, Hampe CS, Ling Z, Pipeleers D, Gorus FK, Martens GA. Development of an Enhanced Sensitivity Bead-Based Immunoassay for Real-Time In Vivo Detection of Pancreatic β-Cell Death. Endocrinology 2015; 156:4755-60. [PMID: 26431226 PMCID: PMC5393343 DOI: 10.1210/en.2015-1636] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
There is a clinical need for plasma tests to detect and quantify the in vivo destruction of pancreatic β-cells in type 1 diabetes. We previously developed a time-resolved fluorescence immunoassay (TRFIA) to glutamate decarboxylase 65 kDa (GAD65) (GAD65-TRFIA) that was able to detect the synchronous necrotic destruction of transplanted β-cells in the hours after their infusion in the liver. This GAD65-TRFIA, however, lacked sensitivity to detect continued β-cell rejection beyond this acute phase. The aim of present study was to gain at least an order of magnitude in analytical sensitivity by switching to Becton Dickinson cytometric bead array (CBA) (GAD65-CBA) enhanced sensitivity format, using the same couple of monoclonal antibodies. We compared the performances of GAD65-CBA and GAD65-TRFIA using Clinical and Laboratory Standards Institute protocols for linearity, imprecision, specificity, limit of detection, and functional sensitivity. We conducted a method comparison and assessed the biologic potential on samples from human recipients of islet grafts. The GAD65-CBA showed acceptable linearity and imprecision. Switching from TRFIA to CBA lowered functional sensitivity by a factor 35 and lowered limit of detection by a factor 11 with minimal need for method optimization. The enhanced sensitivity greatly expands the application domain of our biomarker and allowed for the first time to detect ongoing β-cell destruction up to at least 1 day after islet transplantation. We conclude that the GAD65-CBA is suitable for biological and clinical assessment of the real-time destruction of β-cells in intraportal transplantation.
Collapse
Affiliation(s)
- Olivier R Costa
- Diabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725
| | - Geert Stangé
- Diabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725
| | - Katrijn Verhaeghen
- Diabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725
| | - Benedicte Brackeva
- Diabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725
| | - Ellen Nonneman
- Diabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725
| | - Christiane S Hampe
- Diabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725
| | - Zhidong Ling
- Diabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725
| | - Daniel Pipeleers
- Diabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725
| | - Frans K Gorus
- Diabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725
| | - Geert A Martens
- Diabetes Research Center (O.C., G.S., B.B., E.N., Z.L., D.P., F.K.G., G.A.M.), Brussels Free University and Department of Clinical Chemistry and Radio-Immunology (O.C., K.V., B.B., F.K.G., G.A.M.), Universitair Ziekenhuis Brussel, B1090 Brussels, Belgium; and Department of Medicine (C.S.H.), University of Washington, Seattle, Washington 98109-4725
| |
Collapse
|